Wuxi XDC Cayman’s shares rose in their trading debut in Hong Kong as investors scrambled to compensate for the lost opportunity during the company’s initial public offering.
Shares of the company, a unit of Chinese contract drugmaker Wuxi Biologics HK:2269, opened 31% higher compared with the IPO price of HK$20.60 a share.
The company, which…
Read the full article here
